Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent therapeutic trends and promising targets in triple negative breast cancer
Soo‐Yeon Hwang, Seojeong Park, Youngjoo Kwon
Pharmacology & Therapeutics (2019) Vol. 199, pp. 30-57
Open Access | Times Cited: 204

Showing 1-25 of 204 citing articles:

The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer
Xiaying Zheng, Mengge Huang, Lei Xing, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 350
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Jinhua Liu, Zichao Chen, Yaqun Li, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 308
N6-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification
Qianqing Wang, Xiangcui Guo, Li Li, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 10
Open Access | Times Cited: 215
Pathology of triple negative breast cancer
Filippo Borri, Annarita Granaglia
Seminars in Cancer Biology (2020) Vol. 72, pp. 136-145
Closed Access | Times Cited: 203
Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer
Jean Ogier du Terrail, Armand Léopold, Clément Joly, et al.
Nature Medicine (2023) Vol. 29, Iss. 1, pp. 135-146
Closed Access | Times Cited: 107
Nano-ultrasonic Contrast Agent for Chemoimmunotherapy of Breast Cancer by Immune Metabolism Reprogramming and Tumor Autophagy
Xupeng Yang, Meng Zhao, Zhihua Wu, et al.
ACS Nano (2022) Vol. 16, Iss. 2, pp. 3417-3431
Closed Access | Times Cited: 76
Recent advancements in nanoconstructs for the theranostics applications for triple negative breast cancer
Ashutosh Gupta, Kumar Nishchaya, Moumita Saha, et al.
Journal of Drug Delivery Science and Technology (2024) Vol. 93, pp. 105401-105401
Open Access | Times Cited: 19
Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis
Sima Lev
Biochemical Society Transactions (2020) Vol. 48, Iss. 2, pp. 657-665
Closed Access | Times Cited: 128
CircUBE2D2 (hsa_circ_0005728) promotes cell proliferation, metastasis and chemoresistance in triple-negative breast cancer by regulating miR-512-3p/CDCA3 axis
Dongwei Dou, Xiaoyang Ren, Mingli Han, et al.
Cancer Cell International (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 83
Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes
Anna Diana, Francesca Carlino, E. Franzese, et al.
Cancers (2020) Vol. 12, Iss. 4, pp. 819-819
Open Access | Times Cited: 82
LinTT1 peptide-functionalized liposomes for targeted breast cancer therapy
Nicola d’Avanzo, Giulia Torrieri, Patrícia Figueiredo, et al.
International Journal of Pharmaceutics (2021) Vol. 597, pp. 120346-120346
Open Access | Times Cited: 76
Triple‑negative breast cancer: A run‑through of features, classification and current therapies (Review)
Meghana Manjunath, Bibha Choudhary
Oncology Letters (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 74
Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches
Saikat Ghosh, Ankit Javia, Saritha Shetty, et al.
Journal of Controlled Release (2021) Vol. 337, pp. 27-58
Closed Access | Times Cited: 66
Co‐delivery CPT and PTX prodrug with a photo/thermo‐responsive nanoplatform for triple‐negative breast cancer therapy
Wenhui Zhou, Xiaodong Ma, Jie Wang, et al.
Smart Medicine (2022) Vol. 1, Iss. 1
Open Access | Times Cited: 64
Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review
Edris Choupani, Mohammad Mahmoudi Gomari, Saeed Zanganeh, et al.
Pharmacological Reviews (2022) Vol. 75, Iss. 2, pp. 309-327
Open Access | Times Cited: 39
Exosomal circRNAs in cancer: Implications for therapy resistance and biomarkers
Zhengjun Lin, Yuqiao Ji, Jian Zhou, et al.
Cancer Letters (2023) Vol. 566, pp. 216245-216245
Closed Access | Times Cited: 35
A stable NIR fluorescent probe for imaging lipid droplets in triple-negative breast cancer
Hong Chen, Shuai Guo, Yu Liu, et al.
Sensors and Actuators B Chemical (2023) Vol. 398, pp. 134740-134740
Closed Access | Times Cited: 35
Activated aggregation‐induced emission therapeutics agents for triggering regulated cell death
Yu‐Qiang Zhao, Le Yu, Lanyun Zhang, et al.
Aggregate (2024) Vol. 5, Iss. 3
Open Access | Times Cited: 12
Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer
Yao Chen, Ji-Rui Yang, Chuanqi Wang, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 12
Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth
Anthony Cheung, Alicia M. Chenoweth, Annelie Johansson, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 15, pp. 3298-3315
Open Access | Times Cited: 11
Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast Cancer
Jasmin Linh On, Sakineh Ghaderi, Carina Rittmann, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1078-1078
Open Access | Times Cited: 1
Targeting DNA Damage Response in Prostate and Breast Cancer
Antje M. Wengner, Arne Scholz, Bernard Haendler
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 8273-8273
Open Access | Times Cited: 69
Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis
Chuanrong Chen, Qianqian Guo, Hao Fu, et al.
Biomaterials (2021) Vol. 275, pp. 120988-120988
Closed Access | Times Cited: 54
Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors
Aladdin M. Srour, Nesreen S. Ahmed, Somaia S. Abd El‐Karim, et al.
Bioorganic & Medicinal Chemistry (2020) Vol. 28, Iss. 18, pp. 115657-115657
Closed Access | Times Cited: 51
Prodigiosin/PU-H71 as a novel potential combined therapy for triple negative breast cancer (TNBC): preclinical insights
Mohammed Moustapha Anwar, Manal Shalaby, Amira M. Embaby, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 51
Page 1 - Next Page

Scroll to top